Daiichi Sankyo
Daiichi Sankyo Company, Limited is a Japanese pharmaceutical enterprise that discovers, develops, manufactures, and commercializes innovative prescription medicines and oncology therapeutics worldwide. The company concentrates its operational drug discovery activities around primary therapeutic areas, with a specialized strategic focus on Oncology and Specialty Medicine. Its key commercial pharmaceutical portfolio features breakthrough antibody-drug conjugates (ADCs) such as Enhertu for HER2-positive cancers, alongside Lixiana (edoxaban) for stroke prevention and Prasugrel. Principal revenue drivers consist of global commercial sales of proprietary prescription pharmaceuticals, alongside high-margin licensing royalty revenues and profit-sharing milestone payments from global partners like AstraZeneca. Daiichi Sankyo serves broad global healthcare end markets encompassing oncology specialty clinics, hospital networks, retail pharmacy chains, healthcare providers, and patients across Japan, North America, and Europe. The corporation holds a leading global market position as a premier biopharmaceutical pioneer in antibody-drug conjugate technologies for targeted cancer treatment. Headquartered in Tokyo, Japan, the company's common stock is primary listed on the Tokyo Stock Exchange under the ticker code 4568.
68 of the funds FundTelligence covers report a position in Daiichi Sankyo.
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 68
- Exposure themes
- Cancer, Treatment, Women's Health
Funds holding Daiichi Sankyo
- DNB Fund Women's Health — DNB · 4.25 % (full portfolio disclosed, August 2026)
- DWS Invest CROCI Japan — DWS · 3.37 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI Sectors Plus — DWS · 3.23 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI Global Dividends — DWS · 1.93 % (full portfolio disclosed, June 2026)
- T. Rowe Price Japanese Equity Fund — T. Rowe Price · 1.51 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 1.46 % (full portfolio disclosed, June 2026)
- Life Cycle Global Equity Select Fund — Life Cycle Investment Partners · 1.23 % (full portfolio disclosed, December 2025)
- Danske Invest Japan Index Restricted — Danske Invest · 1.11 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 68 funds holding it.